- Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
- Prothena to Participate in Upcoming Healthcare Conferences
- Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate
- Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights
- Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 20.62 |
---|---|
High | 20.88 |
Low | 20.32 |
Bid | 20.00 |
Offer | 20.88 |
Previous close | 20.56 |
Average volume | 501.66k |
---|---|
Shares outstanding | 53.72m |
Free float | 47.04m |
P/E (TTM) | -- |
Market cap | 1.10bn USD |
EPS (TTM) | -2.80 USD |
Data delayed at least 15 minutes, as of Apr 24 2024 21:00 BST.
More ▼